Investor Presentaiton
◇ Citadel Health
For personal use only
Citadel Group | Investor Presentation | 17
A leading, international clinical workflow
and data specialist
Purpose and Product
> Clinical workflow and data management software for pathology,
cancer care, radiology and maternity vertices
Revenue and Gross Profit (A$m)
21.2
14.9
15.9
26.8
4.0
> Key operating brands are Auslab™/Evolution™ (Pathology),
CHARMⓇ (Oncology/Cancer Care) and Wellbeing (Radiology & Maternity)
19.7
18.3
2.4
1.9
Performance
> Acquisition of Wellbeing in line with strategic growth priorities
22.8
> 10-year extension of Queensland Health contract
> Some delays in projects impacting margins due to impact of Covid-19,
however activity remains robust
16.4
17.3
> ISO 27001 certification
Organic Growth Outlook
> Growth of CHARMⓇ (Oncology/Cancer Care)
> International expansion for pathology and cancer care software into UK market
> Exploratory growth of radiology opportunities in Australia
FY18
Recurring
$26.8 million
FY20 Revenue
FY19
Non-recurring
FY20
⚫Gross Profit
$21.2 million
FY20 Gross ProfitView entire presentation